| scholarly article | Q13442814 |
| P2093 | author name string | Jing Yang | |
| Wei Liu | |||
| Jian Li | |||
| Jing Gao | |||
| Lin Shen | |||
| Juan Li | |||
| Bin Dong | |||
| Xicheng Wang | |||
| Baocai Xing | |||
| Zhongwu Li | |||
| Jingyuan Wang | |||
| Congcong Ji | |||
| P2860 | cites work | Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 |
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
| HER2 activating mutations are targets for colorectal cancer treatment | Q27853193 | ||
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
| Genome remodelling in a basal-like breast cancer metastasis and xenograft | Q28395637 | ||
| β-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: a meta-analysis | Q31118386 | ||
| Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases | Q33913610 | ||
| Wnt/β-catenin and MAPK signaling: allies and enemies in different battlefields | Q34267455 | ||
| Colorectal cancer in Chinese patients: current and emerging treatment options. | Q34352595 | ||
| Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer | Q34921255 | ||
| A non-mitotic role for Aurora kinase A as a direct activator of cell migration upon interaction with PLD, FAK and Src. | Q35029166 | ||
| Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment | Q35067532 | ||
| Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer | Q35119526 | ||
| FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival | Q35195738 | ||
| The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice | Q35227197 | ||
| Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development | Q36299617 | ||
| Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. | Q36633405 | ||
| Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. | Q36843773 | ||
| An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer | Q37013285 | ||
| Evolving treatment of advanced colon cancer. | Q37561119 | ||
| High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial | Q37682595 | ||
| Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. | Q37888979 | ||
| FGFR2 Amplification in Colorectal Adenocarcinoma | Q38694309 | ||
| Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547. | Q38734005 | ||
| Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors | Q38740566 | ||
| High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. | Q38826826 | ||
| Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer | Q39066439 | ||
| PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. | Q40235695 | ||
| Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor | Q40409619 | ||
| Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation | Q40416521 | ||
| Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models | Q41128277 | ||
| Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis | Q42050401 | ||
| Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model | Q42269977 | ||
| Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer | Q43749016 | ||
| Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial | Q45217739 | ||
| Comparison of local immune microenvironment between liver-metastasis colorectal cancer and non-liver-metastasis colorectal cancer | Q45743121 | ||
| Patient-derived xenografts undergo mouse-specific tumor evolution. | Q46291099 | ||
| Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models | Q47203432 | ||
| Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases | Q47306839 | ||
| Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study | Q47556085 | ||
| Rectal Cancer in Asian vs. Western Countries: Why the Variation in Incidence? | Q47673259 | ||
| A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification | Q47695585 | ||
| Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. | Q48164333 | ||
| β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models | Q49547317 | ||
| Wnt/β-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer | Q49788106 | ||
| Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma | Q49793663 | ||
| Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies | Q49837351 | ||
| Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer | Q50057702 | ||
| The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC. | Q50452810 | ||
| Depleted polymorphonuclear leukocytes in human metastatic liver reflect an altered immune microenvironment associated with recurrent metastasis. | Q53077433 | ||
| [Human epidermal growth factor receptor 2 expression in rectal cancer and its clinical implication]. | Q53217380 | ||
| Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. | Q53574200 | ||
| Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single Institution | Q57845858 | ||
| A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine | Q59326990 | ||
| Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer | Q88983845 | ||
| P433 | issue | 12 | |
| P921 | main subject | colorectal cancer | Q188874 |
| liver metastasis | Q18967325 | ||
| P304 | page(s) | 3485-3500 | |
| P577 | publication date | 2019-05-25 | |
| P1433 | published in | Theranostics | Q21051383 |
| P1476 | title | Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis | |
| P478 | volume | 9 |
Search more.